Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

A Preliminary Study on the Inhibitory Effect of Chunghyul-dan on Stroke Recurrence in Patients with Small Vessel Disease

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2007, v.28 no.1, pp.224-236




Sang-kwan Moon (Kyung-Hee University)

Young-suk Kim (Kyung-Hee University)
Hyung-sup Bae
  • Downloaded
  • Viewed

Abstract

Background: Chunghyul-dan is a combinatorial herbal medicine; previous studies reported it had therapeutic effects for microangiopathy, a major part in the progression of small vessel disease, as well as having anti-hypertensive, anti-hyperlipidemic, anti-apoptotic, anti-oxidative, and anti-inflammatory activities. Therefore, we examined the inhibitory effect of Chunghyul-dan on stroke recurrence in patients with small vessel disease. Methods: We prescribed Chunghyul-dan at 600 mg a day to patients with small vessel disease, and monitored stroke recurrence, drug compliances, and adverse effect for 1 year. We then performed follow-up brain MRI to find new vascular lesions after 1 year of Chunghyul-dan medication. For the subjects lost to follow-up, we assessed their prognosis after 1 year by telephone. Results: There were 73 subjects treated with Chunghyul-dan for 1 year; new vascular events were found in 3. Of the 85 subjects lost to follow-up, fifty four could be contacted, and eight of them had stroke recurrence. One year of Chunghyul-dan medication reduced the odds ratio of stroke recurrence by 75% compared to the subjects lost to follow-up and the rate increased to 88%, when adjusted for other relevant risk factors for stroke occurrence. These reductions were much higher than those of aspirin and other kinds of conventional anti-platelets. There was no adverse effect in any of the study subjects. Conclusions: We suggest Chunghyul-dan could be useful for inhibition of stroke recurrence. Further study with a randomized controlled trial is needed to confirm this suggestion.

keywords
Stroke recurence, smal vesel Stroke recurrence, small vessel disease, Chunghyul-dan


Reference

1

Kim YS, (2002) Daio-Orengedokuto inhibits HMGCoA reductase and pancreatic lipase,

2

Cho KH, (2004) Daio-Orengedokudo Works as a Cell-Proliferating Compound in Endothelial Cells,

3

Cho KH, (2004) Inhibitory Effect of Chunghyul-dan in Prostaglandin E2 and Nitric Oxide Biosynthesis of Lipopolysaccharideinduced RAW 264.7 Cells,

4

Yun SP, (2004) Antihypertensive effect Chunghyul-dan on stage I hypertensive patients with stroke,

5

(1990) Special report from the National Institute ofNeurological Disorders and Stroke. Classificationof cerebrovascular diseases III. Stroke.1990,

6

Hayakawa J, (1986) Yakugadu Zasshi. Studies on physicalchemical quality evaluation of crude drugspreparations. III. Analysis of gardenia fruitsand its preparations 1986,

7

Burn J, (1994;) Long-term risk of recurrencestroke after a first-ever stroke. TheOxfordshire Community Stroke Project 1994,

8

Petty GW, (1998) Survival and recurrence after first cerebral infarction: a population- based study in Rochester, Minnesota, 1975 through 1989,

9

Sacco RL, (1994) Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community. The Northern Manhattan Stroke Study,

10

Dominick JH, (2000) Prevention of ischaemicstroke - antiplatelets,

11

The SALT Collaborative Group. Swedish AspirinLow-dose Trial, (1991) of 75 mg aspirinas secondary prophylaxis after cerebrovascularischemic events. Lancet 1991,

12

Diener HC, (1996) European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke,

13

(1994) Antiplatelet Trialists’ Collaboration. Collaborativeoverview of randomized trials of antiplatelettherapy - I Prevention of death and stroke by prolongedantiplatelet therapy in various categories ofpatients. BMJ 1994,

14

Algra A, (1996) Aspirin at any dose above 30 mg offers only modest protection after cerebral ischemia,

15

Hass WK, (1989) Adams HP for theTiclopidine Aspirin Stroke Study Group Arandomized trial comparing ticlopidine hydrochloridewith aspirin for the prevention ofstroke in high risk patients. N Engl J Med1989,

16

Kim YS, (2001) Anti-hyperlipidemic effect of Daehwanghwangryeonhaedok- tang on hyperlipidemia,

17

Cho KH, (2005) Efficacy and Safety of Chunghyul-dan (Qingxie-dan) in Patients with Hypercholesterolemia,

18

Cho KH, (2003) Clinical Assessment on the Safety of Chunghyul-dan (Qingxie-dan),

  • Downloaded
  • Viewed
  • 0KCI Citations
  • 0WOS Citations

Other articles from this issue

Recommanded Articles

상단으로 이동

Journal of Korean Medicine